Cookies help us deliver our services. By using our services, you agree to our use of cookies. More information

Difference between revisions of "Mutschler 2022 MitoFit"

From Bioblast
(Created page with " in prep {{MitoFit page name}} {{Publication |title=Mutschler R (2022) Membranes as therapeutic targets - liposomes as therapeutic options. MitoFit Preprints 2022.10. https:/...")
Β 
Line 1: Line 1:
in prep
{{MitoFit page name}}
{{Publication
{{Publication
|title=Mutschler R (2022) Membranes as therapeutic targets - liposomes as therapeutic options. MitoFit Preprints 2022.10. https://doi.org/10.26124/mitofit:2022-0010
|title=Mutschler R (2022) Membranes as therapeutic targets - liposomes as therapeutic options. MitoFit Preprints 2022.10. https://doi.org/10.26124/mitofit:2022-0010
Line 7: Line 4:
|authors=Mutschler Rainer
|authors=Mutschler Rainer
|year=2022-04-
|year=2022-04-
|journal=MitoFit Prep
|journal=MitoFit Prep
|abstract=Damaged or chemically altered membranes are highly likely to play a central role at the molecular level in many chronic and acute diseases as well as in aging. Damage is often related to inflammatory processes that release large amounts of radical oxygen species (ROS). For several years, membrane replacement has been investigated as a therapeutic option for various diseases. Furthermore, liposomes represent potentially valuable tools for this purpose to force the integration of membrane material into the body's own tissue. Unfortunately, however, this method has not yet arrived in practice. Therefore, we have made our own efforts to establish membrane replacement in our practice, including the therapeutic use of liposomal products of high quality. Here we report on two successfully treated cases. <br><br>
|abstract=Damaged or chemically altered membranes are highly likely to play a central role at the molecular level in many chronic and acute diseases as well as in aging. Damage is often related to inflammatory processes that release large amounts of radical oxygen species (ROS). For several years, membrane replacement has been investigated as a therapeutic option for various diseases. Furthermore, liposomes represent potentially valuable tools for this purpose to force the integration of membrane material into the body's own tissue. Unfortunately, however, this method has not yet arrived in practice. Therefore, we have made our own efforts to establish membrane replacement in our practice, including the therapeutic use of liposomal products of high quality. Here we report on two successfully treated cases. <br><br>
|keywords=membranes, liposomes, phospholipids, phosphatidylcholin, membrane replacement therapy, liposomal formulations, mitochondria,Β  adducts, detoxification|editor=Tindle-Solomon L
|keywords=membranes, liposomes, phospholipids, phosphatidylcholin, membrane replacement therapy, liposomal formulations, mitochondria,Β  adducts, detoxification
|mipnetlab=
|editor=Tindle-Solomon L
}}
}}
{{Labeling
{{Labeling
|organism=Protists
|area=Patients
|pathways=Gp
|diseases=Inherited, Parkinson's
|additional=AOX, Trypanosoma brucei, glycerophosphate shuttle
|injuries=Oxidative stress;RONS
|organism=Human
|additional=liposomes, lipids
}}
}}
in prep
{{MitoFit page name}}

Revision as of 13:02, 7 April 2022

Publications in the MiPMap
Mutschler R (2022) Membranes as therapeutic targets - liposomes as therapeutic options. MitoFit Preprints 2022.10. https://doi.org/10.26124/mitofit:2022-0010

Β»

MitoFit pdf

[ Membranes as therapeutic targets - liposomes as therapeutic options]

Mutschler Rainer (2022-04-) MitoFit Prep

Abstract: Damaged or chemically altered membranes are highly likely to play a central role at the molecular level in many chronic and acute diseases as well as in aging. Damage is often related to inflammatory processes that release large amounts of radical oxygen species (ROS). For several years, membrane replacement has been investigated as a therapeutic option for various diseases. Furthermore, liposomes represent potentially valuable tools for this purpose to force the integration of membrane material into the body's own tissue. Unfortunately, however, this method has not yet arrived in practice. Therefore, we have made our own efforts to establish membrane replacement in our practice, including the therapeutic use of liposomal products of high quality. Here we report on two successfully treated cases.

β€’ Keywords: membranes, liposomes, phospholipids, phosphatidylcholin, membrane replacement therapy, liposomal formulations, mitochondria, adducts, detoxification β€’ Bioblast editor: Tindle-Solomon L


Labels: MiParea: Patients  Pathology: Inherited, Parkinson's  Stress:Oxidative stress;RONS  Organism: Human 





liposomes, lipids 

in prep


MitoFit Preprints         MitoFit Preprints        
Gnaiger 2019 MitoFit Preprints
       
Gnaiger MitoFit Preprints 2020.4
        MitoFit DOI Data Center         MitoPedia: Preprints         Bioenergetics Communications


Mutschler 2022 MitoFit